Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Abstract excerpt

Owing to the prevalence of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs), its constitutive activity, and ability to recapitulate the MPN phenotype in mouse models, JAK2V617F kinase is an attractive therapeutic target. We report the discovery and initial characterization of the orally bioavailable imidazopyridazine, LY2784544, a potent, selective and ATP-competitive inhibitor of janus kinase 2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to Eosinophilic Disorders and Syndromes
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment